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Abstract
• Management of type 2 diabetes mellitus (T2DM) is focused on 
strict glycemic control in order to prevent complications.
• Currently, self-monitoring of blood glucose (SMBG) with 
fingerstick blood sample is the conventional method to assess 
short-term glycemic control. 
• Due to several limitations of SMBG, continuous glucose 
monitoring (CGM) is emerging as a potential replacement for 
SMBG in patients with type 2 diabetes.
• Therefore, this study examines whether CGM leads to greater 
improvement in glycemic control compared to SMBG in 
nonpregnant adults with T2DM.
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Introduction
Methods
• A literature search was performed in November 2019 using 
PubMed, Academic Search Ultimate, and Google Scholar. 
• Search terms used were "type 2 diabetes OR type 2 diabetes 
mellitus AND continuous glucose monitoring OR CGM”.
• Inclusion and exclusion criteria were manually applied for study 
selection. Any duplicate studies were removed.
• Randomized control trials, cohort studies, or case-control studies 
with sample size >100, published in 2014 or later were considered.
• This left a final set of 7 articles for critical appraisal.
6/6 studies report that at least 1 glycemic parameter was 
significantly improved in CGM group compared to SMBG group.
Strengths:
v Diverse clinical settings and countries
v Most (5/7) were randomized control trials
v Study duration of at least 2-3 months 
v Sample size of at least 100 participants
Weaknesses: 
v Lack of demographic diversity in participant pool (most were 
non-Hispanic whites in their 60s)
v Lack of blinding
v Potential for sponsorship bias and observer bias
Discussion 
Note: Images adapted from https://www.hcd.com
Results 
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Impact of Continuous Glucose Monitoring on Glycemic Control 
in Patients with Type 2 Diabetes
• The findings of the 7 studies collectively suggest that CGM may be 
beneficial in improving glycemic control, particularly in patients 
with insulin-treated T2DM.
• CGM can potentially be a useful tool in guiding treatment 
decisions including insulin dose adjustments as well as in serving 
as a basis for patient education and counseling. 
• Limited and variable evidence for benefits of CGM in T2DM 
warrants further focused research in this topic.
• Future studies should involve more accurately represented 
demographics in participant pool and independent, third-party 
researchers to reduce potential sponsorship bias. 
Conclusion
Table 1. Comparison of Results
All 7 studies differed in the glycemic parameter affected by CGM use, as shown in Table 
1. However, at least 1 variable was shown to be significantly associated with the CGM 
use in each of the studies. Notably, the study by Anjana et al. showed that a single 
CGM wear lasting 14 days was enough to produce a clinically meaningful change in 
HbA1c at 3 months. Also, the greatest improvement in glycemic control was seen in 
participants using multiple dose insulin (MDI) injections and in those with baseline 
hyperglycemia of >240 mg/dL, according to the studies by Ajjan et al. and Ruedy et al. 
However, New et al. found that the CGM group with continuous subcutaneous insulin 
infusion (CSII) had a significantly improved glycemic control, while those with MDI did 
not. In the study by Ajjan et al., healthcare providers reported that CGM data aided 
their communication with patients and treatment adjustments. Also, multiple studies 
showed that advanced age did not appear to be a barrier to using CGM devices.
Other findings associated with CGM use
• HbA1c (long-term glycemic control): significant improvement in 4/6 studies
• Diabetes treatment satisfaction: significant improvement in 4/4 studies 
• Diabetes quality of life: significant improvement in 2/3 studies
• In the U.S., 34.1 million adults (age ≥18 years) or 13% of the adult 
population are diagnosed with T2DM.1
• Prevalence of T2DM is the lowest in non-Hispanic whites, higher in 
Asians and Hispanics, and the highest in African Americans.1
• Effective glycemic control is integral to diabetes management in 
order to lower the risk of complications such as retinopathy, 
neuropathy, cardiovascular disease and renal disease.2,3
• SMBG with fingerstick blood sample has traditionally been used to 
monitor short-term glycemic control. However, several barriers 
limit its use, such as discomfort, inconvenience, and high costs.3-6
• CGM technology uses subcutaneously inserted sensors to measure 
real-time interstitial glucose levels throughout the day, providing 
convenience, ease of use and data shareability at lower costs.7-9
• Currently, CGM is the gold standard of care for adults with type 1 
diabetes (T1DM) and used less frequently in those with T2DM.3
• Several studies have shown mixed results regarding whether CGM 
improves glycemic control in patients with T2DM.10, 11
• Therefore, more research is needed to determine the 





<55 mg/dL <70 mg/dL 70-180 mg/dL >180 mg/dL >240 mg/dL
Ajjan et al 
(2019) N/A NS NS
a NS NS
Anjana et al 
(2017) N/A N/A N/A N/A N/A
Haak et al 
(2016) S S NS NS NS
Jangam et al 
(2019) S
a Sa N/A Sa Sa
New et al 
(2015) N/A S
b NS N/A N/A
Ruedy et al 
(2017) N/A N/A S N/A S
Yaron et al 
(2019) N/A N/A N/A N/A N/A
HyperglycemiaHypoglycemia Euglycemia
Key
S = significant improvement compared to control (p ≤ 0.05)
NS = not significant improvement compared to control (p > 0.05)
N/A = not available 
a=Results were compared to baseline values instead of control values.
b=Result was significant in the intervention group that utilized CGM with alarms, while it was insignificant in the intervention group without alarms. 
SMBG CGM
